Published in Medical Patent Law Weekly, February 7th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Alnylam Pharmaceuticals.
This program, in collaboration with University of Texas (UT) Southwestern Medical Center at Dallas, is focused on evaluating new approaches for reducing LDL cholesterol levels using RNAi therapeutics directed to the disease target called proprotein convertase...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly